Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Dr. Orlowski

Home/Tag:Dr. Orlowski
24 11, 2015

Blood Glucose, MGUS, Myeloma & Metformin (Part Four)

Tags: , |9 Comments

Following the news that not one but two new myeloma therapies are newly FDA approved, is it possible that the diabetes drug, meformin, could be a third? Before I post the fourth installment of Danny Parker's series, I wanted to update everyone about how I'm holding up. Following my first auto stem cell transplant this

6 02, 2015

Dr. Orlowski gives shout-out to LGH447

Tags: , , |6 Comments

Wednesday I shared a link to an interview featuring myeloma expert, Dr. Robert Orlowski: New Therapies: M.D Anderson’s myeloma expert: Dr. Robert Orlowski Toward the end of the hour, Dr. Orlowski mentioned a new, experimental myeloma drug that I had only heard about in passing: LGH447. I don't know a lot about it.  I do

9 02, 2013

Everything you always wanted to know about POM but were afraid to ask…

Tags: , , , , , , , , , , , , |4 Comments

The internet is flooded with excitement following the FDA's limited approval of celgene's newest IMiD, pomalidomide (trade name, POMALYST).  POM is an analogue of thalidomide (trade name, Thalomid).  Researchers actually developed POM before Revlimid, but sat on it for a decade--choosing to intensify clinical study activity recently, culminating in yesterday's FDA approval. I'm going to

7 12, 2012

Dr. Orlowski’s myeloma therapy overview

Tags: , , |2 Comments

Dr. Robert Orlowski is presenting his overview of the myeloma therapy landscape right now.  Sort of an overview of international treatment options. No new news so far.  This isn't surprising, considering his data does not include new things from these meetings. It was interesting to note that Thalomid maintenance therapy studies show a superior overall

14 04, 2012

Another new myeloma antibody continues to impress…

Tags: , , , , |14 Comments

Here is some follow-up on a more well tested anti-myeloma antibody, Elotuzumab--the kind of therapy you will find featured in my new myeloma therapies book. A number of top myeloma experts, including Doctors Jakubowiak, Jagannath, Durie and Orlowski are big fans. This article is from an online trade publication called OncLive.com: Elotuzumab Responses High in

14 12, 2011

International Myeloma Foundation’s Journalist Workshop features multiple myeloma related highlights from ASH

Tags: , , , , , , , |0 Comments

I just finished writing an article about Monday’s night International Myeloma Foundation’s Journalist Workshop.  I will provide a link to the article as soon as it runs on the IMF’s website. Here’s an excerpt/preview from the article as I set the scene from the 90 minute media event: Monday evening I attended the IMF’s post-ASH

6 12, 2010

Dr. Robert Orlowski From M.D. Anderson Previews Exciting, Positive New Therapy Data To Be Revealed At ASH

Tags: , , , , , , , |1 Comment

As promised, here is the final installment of my three part report on the IMF's ASH kick-off panel discussion Friday evening at the Peabody Hotel in Orlando:I have already written two articles about Friday evening’s IMF panel of experts program, Key Myeloma Questions for 2010: Latest Developments in Diagnosis, Prognosis and treatment.Let’s conclude with M.D.

6 12, 2010

Reflections Before Opening The Flood Gates Of Technical Multiple Myeloma Related Information From This Year’s ASH

Tags: , , , , , |1 Comment

I wanted to share my thoughts from ASH after a very busy weekend.  On our other daily site, http://www.helpwithcancer.org/, I am reporting about non-multiple myeloma related news from this year's meetings.  You can imagine how difficult it is to determine which studies are most significant when dealing with dozens and dozens of hematological cancers.  I